Singapore Clinical Trial: Role of glucagon-like peptide 1 receptor Agonist (GLP1 RA) Dulaglutide on cerebral hemodynamics In patients with severe and symptomAtic steNosis of inTracranial internal carotid artery or middle cerebral artery with impaired cerebral vasodilatory reserve- an open-label randomised clinical trial (RADIANT)

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'Role of glucagon-like peptide 1 receptor Agonist (GLP1 RA) Dulaglutide on cerebral hemodynamics In... Read More

Singapore Clinical Trial: A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the effi... Read More

Singapore Clinical Trial: A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the efficacy in reducing atrial fibrillation burden (AFB) as well as the safety, tolerability, and pharmacokinetics of oral PKN605 in participants with atrial fibrillation

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the effi... Read More

Singapore Clinical Trial: A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab Adizutecan in Combination with Osimertinib as First-Line Treatment in Patients with Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab A... Read More

Singapore Clinical Trial: A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Retained Gastric Contents Using Gastric Ultrasound in Participants with Type 2 Diabetes Mellitus and Participants with Overweight or Obesity without Type 2 Diabetes Mellitus.

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Ret... Read More

Singapore Clinical Trial: A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy in Participants With 1L Locally Advanced Unresectable/Metastatic Esophageal Cancer: KEYMAKER-U06 Substudy 06E

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination Wi... Read More

Singapore Clinical Trial: EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease

Singapore, April 6 -- The Health Sciences Authority received information related to the study titled 'EASi-PROTKT™ - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate ... Read More

Q4 అప్‌డేట్స్ ఎఫెక్ట్: కుదేలైన బ్యాంకింగ్ షేర్లు.. కోటక్, ఇండస్ఇండ్‌లకు భారీ నష్టాలు

భారతదేశం, ఏప్రిల్ 6 -- వారాంతంలో పలు ప్రముఖ బ్యాంకులు విడుదల చేసిన నాలుగో త్రైమాసిక (Q4FY26) వ్యాపార గణాంకాల ప్రభావం సోమవారం నాటి స్టాక్ మార్కెట్‌పై స్పష్టంగా కనిపించింది. బ్యాంకింగ్ రంగ షేర్లలో ఇన్వె... Read More

Pharma Stock in Focus After Board Approves Buyback of Shares Worth Rs800 Cr

India, April 6 -- A major Indian pharma giant board approved a Rs800 crore share buyback on April 6, offering shareholders Rs1,475 per share, about 10.9% above the market price. The tender offer cover... Read More

Fitch Publishes 'A(lka)' Rating on WindForce's Proposed Debentures

Sri Lanka, April 6 -- Fitch Ratings has published the National Long-Term Rating of 'A(lka)' on WindForce PLC's proposed senior unsecured redeemable debentures of up to LKR4 billion. The notes are rate... Read More

• ««
• «
• 17682
• 17683
• 17684
• 17685
• 17686
• 17687
• 17688
• 17689
• 17690
• 17691
• »
• »»